地塞米松植入剂与局部碳酸酐酶抑制剂治疗双侧视网膜色素变性相关囊样黄斑水肿患者的对比:一项前瞻性配对眼先导研究
这项前瞻性配对眼先导研究纳入9例双侧视网膜色素变性相关囊样黄斑水肿患者,一眼接受玻璃体内地塞米松植入剂、对侧眼接受局部碳酸酐酶抑制剂,随访12个月。地塞米松植入剂眼在治疗后第1个月和第7个月黄斑中心厚度显著低于局部碳酸酐酶抑制剂眼,但第12个月局部碳酸酐酶抑制剂眼最佳矫正视力更好(临界显著P=0.0510),两组微视野敏感度无差异,3例患者在地塞米松植入剂后出现眼压升高。
要点
- 地塞米松植入剂眼在治疗后1个月和7个月黄斑中心厚度显著低于局部碳酸酐酶抑制剂眼。
- 第12个月局部碳酸酐酶抑制剂眼最佳矫正视力更好,原文报告P=0.0510为临界显著。
- 9例中3例在地塞米松植入剂后出现眼压升高,5例出现对侧眼效应。
核心结论
- 玻璃体内地塞米松植入剂在治疗后1个月减轻视网膜色素变性相关囊样黄斑水肿方面比局部碳酸酐酶抑制剂更有效。
- 糖皮质激素可在视网膜色素变性相关囊样黄斑水肿的管理中发挥关键作用,但其给药途径、时机和给药方式应进一步探索。
研究设计与样本
- 前瞻性配对眼先导研究,双眼视网膜色素变性相关囊样黄斑水肿患者一眼接受玻璃体内地塞米松植入剂、对侧眼接受局部碳酸酐酶抑制剂。
- 共招募9例患者,随访12个月。
- 主要终点为黄斑中心厚度变化,次要终点为最佳矫正视力和微视野中心视网膜敏感度变化,并评估眼压及其他眼部并发症以评价安全性。
主要发现
- 地塞米松植入剂眼黄斑中心厚度在治疗后第1个月和第7个月显著低于局部碳酸酐酶抑制剂眼。
- 第12个月局部碳酸酐酶抑制剂眼平均最佳矫正视力更好,原文报告P=0.0510为临界显著。
- 两种治疗之间微视野敏感度无差异。
- 3例患者在地塞米松植入剂后出现眼压升高。
- 9例患者中5例观察到地塞米松植入剂对侧眼效应。
局限性
- 原文结论指出糖皮质激素的给药途径、时机和给药方式应进一步探索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare within-subject efficacy and safety of intravitreal dexamethasone implant and topical carbonic anhydrase inhibitors in the treatment of retinitis pigmentosa-related cystoid macular edema. METHODS: Patients with bilateral retinitis pigmentosa-related cystoid macular edema were treated with intravitreal dexamethasone implant in one eye and topical carbonic anhydrase inhibitors in the contralateral eye. The primary endpoint was a change in central macular thickness. Secondary endpoints were changes in best-corrected visual acuity and microperimetric central retinal sensitivity. Intraocular pressure and other ocular complications were evaluated for safety assessment. RESULTS: Nine patients were recruited for this 12-month follow-up study. Central macular thickness was significantly lower in intravitreal dexamethasone implant-treated eyes than in topical carbonic anhydrase inhibitors-treated eyes at Months 1 and 7, whereas mean best-corrected visual acuity was better in eyes treated with topical carbonic anhydrase inhibitors at Month 12 (borderline significant P = 0.0510). There was no difference in microperimetric sensitivity between the two treatments. Three patients developed ocular hypertension after intravitreal dexamethasone implant. Intravitreal dexamethasone implant showed an effect on the contralateral eye in five of nine patients. CONCLUSION: Intravitreal dexamethasone implant was more effective than topical carbonic anhydrase inhibitors in reducing retinitis pigmentosa-related cystoid macular edema 1 month after treatment. Corticosteroids can play a key role in the management of retinitis pigmentosa-related cystoid macular edema; however, their routes, timing, and modes of administration should be further explored.
引用
- Colombo L, Montesano G, Di Domenico A, et al. DEXAMETHASONE IMPLANT VERSUS TOPICAL CARBONIC ANHYDRASE INHIBITORS IN PATIENTS WITH BILATERAL RETINITIS PIGMENTOSA-RELATED CYSTOID MACULAR EDEMA: A Prospective, Paired-Eye Pilot Study. Retina. 2024. PMID: 38166238. doi:10.1097/IAE.0000000000004039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。